Loading stock data…
MapLight Therapeutics (MPLT)
$36.56+1.33 (+3.78%)
Market ClosedLast close Jul 24
MapLight Therapeutics, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$64.50M↑ | -$83.38M↓ | -$31.50M | — | -$23.54M |
| Net Income | -$60.67M↑ | -$79.55M↓ | -$29.42M | — | -$22.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.01%
Volume
Today's trading volume
545,688
Recent News
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the best biotech stocks on this list. TheFly reported on June 24 that Raymond James initiated coverage of MPLT with a Strong Buy rating and a $46 price target. The firm highlighted Cobenfy as […]
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.